EUROPE COMPANY RESULTS
Despite the sluggish European economy, revenues increased for most firms
(Monetary figures, except per-share amounts, are in millions of dollars)
|
YEAR |
NET SALES ($) |
EARNINGS ($) |
PROFIT MARGIN (%) |
TOTAL ASSETS ($) |
STOCKHOLDERS' EQUITY ($) |
RETURN ON EQUITY (%) |
CAPITAL SPENDING, % OF SALES |
R&D SPENDING, % OF SALES |
EARNINGS PER SHARE ($) |
DIVIDEND, $ PER SHARE |
DIVIDEND YIELD, % OF PRICE |
STOCK PRICE RANGE, PER SHARE |
PRICE/EARNINGS RATIO |
| HIGH |
LOW |
NOTE: Monetary statistics, except stock prices, for all years were converted at the 2012 average exchange rate of $1.00 U.S. = 0.7777 euros, 0.9377 Swiss francs, and 0.6308 pounds sterling. a Sold its pharmaceuticals unit and changed its accounting procedures in 2010; bought Rhodia in 2011. b Spun off Tikkurila in 2010. c Acquired Ciba in 2009. d Purchased Millipore in 2008. e Purchased Sud-Chemie in 2011. f Purchased Arch Chemicals in 2011. def = deficit. ne = nonexistent.
Click on the arrows to sort table.
If you are having trouble viewing this table, click here for a PDF.
Back to Finance: No Growth, No Problem
